Connect your AI

Vaxcyte, Inc. PCVX Lease Liability Payments - 2020 (Remaining Three Months)

Lease Liability Payments - 2020 (Remaining Three Months) at other companies

ModernaMRNA

——

Krystal Biotech, Inc.KRYS

——

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

Operating income-$345.9M-91.3%

Net income-$320.6M-128%

EPS (diluted)-$2.30-121%

Balance sheet

Cash & equivalents$262.3M-24.7%

Total debt$116.3M+33.5%

Total equity$3.0B-6.4%

Total assets$3.3B-0.9%

Cash flow

Operating cash flow-$280.6M-68.8%

CapEx$2.1M-61.2%

Free cash flow-$282.7M-64.7%

Valuation

Market cap$7.43B+72.0%

Enterprise value$7.28B+78.6%

Returns & leverage

Return on equity-30.6%+37.9pp

Debt / equity0×0.0×

Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s lease liability payments - 2020 (remaining three months).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Vaxcyte, Inc.'s lease liability payments - 2020 (remaining three months)?: Vaxcyte, Inc. (PCVX) reported lease liability payments - 2020 (remaining three months) of $8.93M in Q1 2026.
How has Vaxcyte, Inc.'s lease liability payments - 2020 (remaining three months) changed year-over-year?: Vaxcyte, Inc.'s lease liability payments - 2020 (remaining three months) increased by 8.8% year-over-year, from $8.21M to $8.93M.